KU-55933 (ATM Kinase Inhibitor)

Catalog No.S1092

KU-55933 (ATM Kinase Inhibitor) Chemical Structure

Molecular Weight(MW): 395.49

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

Size Price Stock Quantity  
In DMSO USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 370 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 75 Publications

Purity & Quality Control

Choose Selective ATM/ATR Inhibitors

Biological Activity

Description KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.
Targets
ATM [1]
(Cell-free assay)
12.9 nM
In vitro

KU-55933 inhibits DNA-PK and PI3K with IC50 of 2.5 μM and 16.6 μM, respectively. Besides, KU-55933 also prevents the activity of mTOR with IC50 of 9.3 μM. KU-55933 is active at the cellular level in ablating a well-characterized ATM-dependent phosphorylation event. KU-55933 has a dose-dependent effect in inhibiting this ATM-dependent phosphorylation event with IC50 of 300 nM. KU-58050 does not prevent the ATM-dependent phosphorylation of p53 serine 15 until a dose of 30 μM. Addition of KU-55933 has no appreciable effects on UV-induced phosphorylation of H2AX on serine 139, NBS1 on serine 343, CHK1 on serine 345, and SMC1 on serine 966. In stark contrast to the UV responses, KU-55933 ablates the ionizing radiation-induced phosphorylation of these ATM substrates. KU-55933 sensitizes HeLa cells to a range of ionizing radiation doses. [1] KU-55933 inhibits the phosphorylation of Akt induced by growth factors in cancer cells. KU-55933 suppresses the proliferation of cancer cells. Furthermore, suppression of ATM by KU-55933 improves survival, probably via prevention of downstream activation of TAp63α. [2]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-145 NEjNUJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;SZ2lEPTB;Mz6yO|M2OiEQvF2= MV7TRW5ITVJ?
HuO-3N1 NYHsfVRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjPN2lEUUN3ME20MlE4OTR{IN88US=> M1zzOnNCVkeHUh?=
LAMA-84 NFXSW|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTRwNUi0OlUh|ryP NGPVbJhUSU6JRWK=
CAL-72 NEG5bmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7xOJpKSzVyPUWuOFgxQDRizszN M2XjNHNCVkeHUh?=
LoVo M1HhdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTZwOUOyN|kh|ryP M3m3UHNCVkeHUh?=
HH M4q0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRThwMke2O|Eh|ryP MoS0V2FPT0WU
SK-MEL-3 NIr1Um5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRThwMki1O|Uh|ryP MUfTRW5ITVJ?
KM12 NH3Md4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33QcGlEPTB;OT6yNVE1OiEQvF2= NEX2eGVUSU6JRWK=
NCI-H1437 Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LtN2lEPTB;OT64NFk4KM7:TR?= M37zXXNCVkeHUh?=
NCI-H1838 NGCzco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTFzLkG4OlUh|ryP MoTlV2FPT0WU
J-RT3-T3-5 NHnv[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFK1PXVKSzVyPUGxMlI1OTdizszN M2HYSHNCVkeHUh?=
GOTO NHrpN3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDUN5JKSzVyPUGxMlY6QTZizszN M2jPbnNCVkeHUh?=
LB2241-RCC NHm2WFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTlTWM2OD1zMT63NVg3KM7:TR?= NYjXcGJ3W0GQR1XS
ES7 M2i2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTFzLke4PEDPxE1? MmLCV2FPT0WU
KP-N-YS NGjmOY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfiOmhrUUN3ME2xNk43OzV2IN88US=> MYXTRW5ITVJ?
CAL-12T MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfEWWNKSzVyPUGzMlYyPyEQvF2= NU[1SZpTW0GQR1XS
COLO-684 M4LvfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzMcIJZUUN3ME2xOE4yPTZ7IN88US=> M3HB[HNCVkeHUh?=
DOK NVzjV5R2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnJTWM2OD1zNT6zN|I6KM7:TR?= MYnTRW5ITVJ?
Hs-578-T MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvjVXFKSzVyPUG1MlQyQDJizszN NUKyWZZDW0GQR1XS
D-423MG NYDYb2pHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXe2[2w6UUN3ME2xOU42OjN4IN88US=> M3TZU3NCVkeHUh?=
DBTRG-05MG MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7MdI1KSzVyPUG1MlYyOTFizszN Ml3wV2FPT0WU
VM-CUB-1 NX6wZZY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF3Lkm4OFkh|ryP M2\jTnNCVkeHUh?=
KG-1 M2WwNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTF4LkC5PVYh|ryP M2jVc3NCVkeHUh?=
8305C Mn[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnnO4dKSzVyPUG2MlE5QDlizszN Mn25V2FPT0WU
HuH-7 M1[5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkf0TWM2OD1zNj6yOlc1KM7:TR?= MlK5V2FPT0WU
LXF-289 MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjTSmVKSzVyPUG2MlI4PDdizszN M2jXcXNCVkeHUh?=
NCI-H1793 NX;W[phzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlu4TWM2OD1zNj60O|EzKM7:TR?= NXfKRYdIW0GQR1XS
ChaGo-K-1 NIDKNmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTF4Lk[1Olgh|ryP NYrvOnl4W0GQR1XS
GCIY NF7KZ3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmS1TWM2OD1zNj63PVA2KM7:TR?= Mnv4V2FPT0WU
SK-MEL-28 NX7zXXdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fJTGlEPTB;MUeuNFQ4PSEQvF2= M4H2T3NCVkeHUh?=
NCI-SNU-1 MmryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonDTWM2OD1zNz6xNlY6KM7:TR?= NFfUfYdUSU6JRWK=
CTB-1 MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvLR|BmUUN3ME2xO{4zOjV7IN88US=> M4HiRXNCVkeHUh?=
NCI-H82 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojmTWM2OD1zNz60OVc{KM7:TR?= M2D6[3NCVkeHUh?=
HCC2998 NHfjUWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUf1W3NHUUN3ME2xO{43PzN|IN88US=> MWHTRW5ITVJ?
NCI-H2030 M1rBdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1K3TmlEPTB;MUiuNVk6PyEQvF2= MYPTRW5ITVJ?
HuP-T3 MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\GUYhKSzVyPUG4MlU5QDhizszN MnvOV2FPT0WU
697 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXKOYJKSzVyPUG5MlAzODFizszN M1nkTXNCVkeHUh?=
MLMA M3W4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHpNnhHUUN3ME2xPU4xPTV5IN88US=> NF33U4JUSU6JRWK=
HCC70 NVrwcIQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[yTWM2OD1zOT60PFkh|ryP M2HKXnNCVkeHUh?=
A704 MoC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTF7LkizNFUh|ryP Mn3sV2FPT0WU
D-283MED NH;sRoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17PWGlEPTB;MkCuOVM{QSEQvF2= MWnTRW5ITVJ?
U031 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HXfGlEPTB;MkGuNVQ5QSEQvF2= MXnTRW5ITVJ?
HSC-3 NH;WdYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTJzLkG4N|Uh|ryP M3HUfXNCVkeHUh?=
JVM-3 NIPKSpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTJ{LkWwOkDPxE1? MUnTRW5ITVJ?
Mewo MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHzTZJKSzVyPUKyMlUxPzNizszN MYnTRW5ITVJ?
YH-13 NFi5e|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJ{LkWxNlMh|ryP M{Dhe3NCVkeHUh?=
LB1047-RCC M2PhUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnpdJpKSzVyPUKyMlU5PzlizszN M2jrS3NCVkeHUh?=
HCC2157 NVTkW|AyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHETWM2OD1{Mj64NFU1KM7:TR?= MlnoV2FPT0WU
SNU-449 MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTJ{Lki3OFgh|ryP NXvJV3lnW0GQR1XS
Ramos-2G6-4C10 M3Ttd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfGTWM2OD1{Mj65OkDPxE1? NHvUXJVUSU6JRWK=
CHL-1 MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{KzfGlEPTB;MkOuO|I6OiEQvF2= MVHTRW5ITVJ?
SK-MEL-30 M1L1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;JNWlEPTB;MkSuOFY3OiEQvF2= NGm3c4lUSU6JRWK=
PANC-08-13 NWjkOY1{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJ3LkC5N|gh|ryP NV3ub|dNW0GQR1XS
QIMR-WIL NIiwXIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTJ3LkG4OVgh|ryP Mm\4V2FPT0WU
BFTC-905 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGD3SXhKSzVyPUK1MlU6PDRizszN M1;xeXNCVkeHUh?=
GI-1 MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJ3LkewOVUh|ryP MX3TRW5ITVJ?
MDA-MB-415 MkLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[1XWdqUUN3ME2yOk42ODN|IN88US=> MnjUV2FPT0WU
GT3TKB NEPkU2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVW2WZVnUUN3ME2yOk42OzR{IN88US=> MUHTRW5ITVJ?
DEL MlrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\vTmlEPTB;Mk[uPFM2PiEQvF2= Mm\RV2FPT0WU
KOSC-2 M4\5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjsOFFyUUN3ME2yOk46ODd3IN88US=> MV\TRW5ITVJ?
RVH-421 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33acGlEPTB;MkeuNlkzOSEQvF2= MULTRW5ITVJ?
EW-13 NUDXVVF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrUV4xqUUN3ME2yO{41OzB6IN88US=> MYfTRW5ITVJ?
639-V M3m3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HCSWlEPTB;MkeuOVEyQSEQvF2= NVrDUHJFW0GQR1XS
A2780 M4DJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\qTWM2OD1{Nz62OFEh|ryP NHyxOYZUSU6JRWK=
SW982 Mm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nVOWlEPTB;MkeuPVA2OiEQvF2= M2CwVHNCVkeHUh?=
SW1710 NHy1PFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXX[5l4UUN3ME2yPE4xQThzIN88US=> MWfTRW5ITVJ?
HCC1569 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTJ6LkS4PVch|ryP NIjqNVJUSU6JRWK=
MV-4-11 MnW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGO1T4xKSzVyPUK4MlU4OzVizszN M1f1WnNCVkeHUh?=
BHT-101 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TJVmlEPTB;MkiuOlU4OiEQvF2= M3nsUXNCVkeHUh?=
Ca9-22 NEjydm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\tXmFKSzVyPUK4MlcyPCEQvF2= NX;5cZhtW0GQR1XS
HAL-01 M4i0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HEVmlEPTB;MkiuO|YyPSEQvF2= NEPtdmpUSU6JRWK=
D-263MG MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTJ7LkO0OEDPxE1? NHizUHdUSU6JRWK=
NEC8 M2HGNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIn2bWtKSzVyPUK5MlU2PDhizszN NXXMS|VCW0GQR1XS
EKVX M2LOdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjuU5pQUUN3ME2zNU42QDR5IN88US=> MnPiV2FPT0WU
EM-2 NX3J[JNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTNzLk[zNFQh|ryP NVjSOVdYW0GQR1XS
MFM-223 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnk[G9KSzVyPUOxMlgxQThizszN M{\mR3NCVkeHUh?=
SK-PN-DW M{i0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn34TWM2OD1|Mj6xOFA3KM7:TR?= NXvIbYdUW0GQR1XS
HuO9 NETydmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTN{LkWyPFIh|ryP MVTTRW5ITVJ?
MHH-PREB-1 NW\jUo5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkGwTWM2OD1|Mj62NlM1KM7:TR?= Mn[zV2FPT0WU
OVCAR-4 M3nDTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIqzeWFKSzVyPUOyMlg{PjNizszN MonqV2FPT0WU
NCI-H1648 NFLGb5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTN{Lki2OVEh|ryP M1zWbHNCVkeHUh?=
MKN1 Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTN2LkGxNFEh|ryP MYLTRW5ITVJ?
KYSE-450 NHrEc2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\OW3JiUUN3ME2zOE43PDR2IN88US=> MlPGV2FPT0WU
ES8 NEfXSHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTN2Lki5O|Uh|ryP NYXy[HRRW0GQR1XS
MS-1 NWrwXIpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXBeZcyUUN3ME2zOE46PTV2IN88US=> MX;TRW5ITVJ?
HOP-92 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XkfWlEPTB;M{WuPVI4PyEQvF2= M1PNNnNCVkeHUh?=
SKG-IIIa MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnYdG91UUN3ME2zOk4zPTZzIN88US=> MYPTRW5ITVJ?
TE-11 NUDtN|FJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrnNW5KSzVyPUO2MlUzPDNizszN M33le3NCVkeHUh?=
SK-NEP-1 MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTiWm54UUN3ME2zO{43PzR2IN88US=> NY\IWFJnW0GQR1XS
DB M4HCbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjWVmFKSzVyPUO3MlkyQDVizszN M2S5WHNCVkeHUh?=
IA-LM MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXHeZdRUUN3ME2zPE4xOjN7IN88US=> MV3TRW5ITVJ?
COLO-829 NEHaWW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTN6LkSxOVkh|ryP MVjTRW5ITVJ?
TGBC11TKB Mn;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTN7LkG0NFgh|ryP NWnacFBFW0GQR1XS
CAL-51 NH7tcJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGmyeY5KSzVyPUSwMlA3OTJizszN NIrRb2VUSU6JRWK=
NCI-H2228 NYLx[5puT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2noOWlEPTB;NECuN|Y3OiEQvF2= NXzGdohTW0GQR1XS
C32 NGPIcJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLVc4FYUUN3ME20NE41ODJ2IN88US=> MX\TRW5ITVJ?
KU-19-19 NGKwfW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLjTWM2OD12MD63Olg{KM7:TR?= NF;qcJZUSU6JRWK=
KNS-62 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;FVW5KSzVyPUSwMlg{QDFizszN NE\SdXJUSU6JRWK=
FADU NHW3O4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn21TWM2OD12MT6yOVAzKM7:TR?= MYnTRW5ITVJ?
CAL-33 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGG0dYZKSzVyPUSyMlY4PDlizszN MnXPV2FPT0WU
CHP-134 MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fZV2lEPTB;NEKuPFQ6PiEQvF2= NI\EVodUSU6JRWK=
HDLM-2 M3\FUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljiTWM2OD12Mj65NFg1KM7:TR?= MnrkV2FPT0WU
NBsusSR NFfHdldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLOTWM2OD12Mz6wO|I2KM7:TR?= NIT0e5hUSU6JRWK=
SW954 NF\pd|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfxTWM2OD12Mz6xNFU{KM7:TR?= M4f5bnNCVkeHUh?=
HCC1806 M3\mSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPmVppGUUN3ME20N{41OTFizszN M3vYWXNCVkeHUh?=
VMRC-RCZ M3rSSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDNTWM2OD12Mz60OVg3KM7:TR?= NGq1SHZUSU6JRWK=
A549 NGCxZo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEe4R|VKSzVyPUSzMlk{OSEQvF2= MXvTRW5ITVJ?
NKM-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrBdHhKSzVyPUSzMlk2PThizszN MX3TRW5ITVJ?
DMS-273 M2fQTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\5dI5KSzVyPUS0Mlc2PjdizszN NFPxOpRUSU6JRWK=
TYK-nu M4PZ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jae2lEPTB;NEWuNVI{PCEQvF2= NH7Bdo1USU6JRWK=
KALS-1 NW\yeoJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LueGlEPTB;NEWuNVQ3KM7:TR?= NH71VWtUSU6JRWK=
A101D MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\6UWlEPTB;NEWuOFQ2PiEQvF2= MX3TRW5ITVJ?
G-361 NFHpVnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HKOGlEPTB;NE[uNlE{QCEQvF2= NUTlXYhxW0GQR1XS
KARPAS-299 M1H6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jpcGlEPTB;NE[uN|UyPiEQvF2= Mki4V2FPT0WU
RS4-11 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nhVmlEPTB;NE[uOVQzKM7:TR?= NEDKSm9USU6JRWK=
HT-1376 NGP4e2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvqcYxKSzVyPUS2Mlc1OjZizszN MYPTRW5ITVJ?
SK-N-AS M4fYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;2UHl4UUN3ME20Ok44QDJ{IN88US=> NEnMeWpUSU6JRWK=
MG-63 NI\6S4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnHbVNKUUN3ME20Ok46ODN4IN88US=> MluxV2FPT0WU
EPLC-272H NGPSUXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3pXFdsUUN3ME20Ok46PTB|IN88US=> MVnTRW5ITVJ?
BALL-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonzTWM2OD12Nz64N|Ih|ryP NF\PPWlUSU6JRWK=
LCLC-97TM1 NVnGb|VvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjX[5kzUUN3ME20PE4zODJizszN MVrTRW5ITVJ?
HO-1-N-1 Ml7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTtdYsyUUN3ME20PE46Pjd4IN88US=> NIHxOVFUSU6JRWK=
MFE-280 M{LNWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTR7LkS2NVch|ryP MmDSV2FPT0WU
NCI-H526 MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1T2e2lEPTB;NEmuPFE3OyEQvF2= MoC2V2FPT0WU
D-566MG MlPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37Gd2lEPTB;NEmuPVA6PiEQvF2= NFHyN4dUSU6JRWK=
BB30-HNC NF\m[ZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LGNmlEPTB;NEmuPVQ6QCEQvF2= MmLrV2FPT0WU
SK-N-DZ NF7BRVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrvbG1{UUN3ME21NE4xPDhzIN88US=> M1vVenNCVkeHUh?=
HepG2  NEL4VphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrXTIVGOTEEoN88US=> NVGxS5pbOjRiaB?= M4XXfIJtd2OtczDTR{1KUUl|LXnu[JVk\WRiUzDwbIF{\SCjcoLld5Q> NUj1TFloOjV3MkexNlM>
HepG2  M1r0cGZ2dmO2aX;uJGF{e2G7 MmfQNVDDqM7:TR?= MkTxNlQhcA>? M1;ZOpN2eHC{ZYPz[ZMhfGinIIDoc5NxcG:{eXzheIlwdnNib3[gRXROKG:wIGPldlE6QDFuIFPob|Ehd25iU3XyN|Q2NCCFaHuyJI9vKFSqck[4MEBidmRiQ3TrNkBwdiCWeYKxOUBqdmS3Y3XkJIJ6KFOFLVnJTVM> NUjRRVFDOjV3MkexNlM>
KATO III  NWrVU|dpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUn5UGtNOi53L{WvO{42KM7:TR?= M4XtXWROW09? NYL4N4VO\W6qYX7j[ZMhfGinIITvfIlkcXS7IH;mJI9t[XCjcnni NFrLS44zPDh2MUexPC=>
hTCEpi NVuwNJJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlewNVAh|ryP NHfKfFFFVVOR NV3HRmk3eHKndnXueJMhfGinIHP5eI9x[XSqaXOg[YZn\WO2IH;mJGhUXi1z Ml23NlQ{PzB6M{W=
MCF10A NWPmW5M4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NESzfWYyOCEQvF2= MX[yOEBp MVHEUXNQ NUT5T2dSeG:2ZX70bYF1\XNidHjlJIN6fG:2b4jpZ4l1gSCxZjDHRS=> MViyOFE2ODV7NR?=
HL-60  NIXjSnhHfW6ldHnvckBCe3OjeR?= M{XMcVExKM7:TR?= MYqwMlUhcA>? NXnBPJV{TE2VTx?= MmnMdoVlfWOnczDwbI9{eGixconsZZRqd25ib3[gR4hsOsLi NEnnRXMzOzl|NESxNS=>
MCF-7 MkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfoRlQyNTFyMN88US=> MonSNlQhcA>? NEWyeVNHSlN? M3PVSolvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25? NXPoXXY5OjNzOEWzOFc>
HeLa  NHj4PVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjzN5UyOS1zMEFOwG0> NFHDVo4zPCCq M2TzOmZDWw>? M4jabolvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25? MVuyN|E5PTN2Nx?=
SH-SY5Y MYfGeY5kfGmxbjDBd5NigQ>? NUHy[JU6OTEEoN88UeKh M3HTVlI1KGh? MX;pcohq[mm2czDjcIlweXWrbn;sMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJJA2Ow>? MljCNlI3Ojd{OUS=
IMR-32 M2TsUWZ2dmO2aX;uJGF{e2G7 M1PRclExyqEQvF5CpC=> M2PkSFI1KGh? MoHlbY5pcWKrdIOgZ4xqd3G3aX7vcE1qdmS3Y3XkJJBpd3OyaH;yfYxifGmxbjDv[kBxPTN? NWPLZoNQOjJ4MkeyPVQ>
A549 MmHMSpVv[3Srb36gRZN{[Xl? M{PpRlExyqEQvF5CpC=> M1Xo[|EhcA>? NVewdFVUe3WycILld5NmeyCQYX7vMWNwNWmwZIXj[YQheDV|IHHjZ5VufWyjdHnvci=> NWDVXG94OjJ3NUmzNlE>
T47D  Ml:3SpVv[3Srb36gRZN{[Xl? Ml6xNlDDqG2P NHjBeGIzPCCq NWf0S25WTE2VTx?= M4HMbJBz\X[nboTzJGlTNWmwZIXj[YQh\GWpcnHkZZRqd25ib3[gTe67Ss7z M17oXlIyOTR2OEC1
A29 MEF M3nsZmZ2dmO2aX;uJGF{e2G7 MnPCNVDDqM7:TdMg M2PmcFFp NXPhdHp[[myxY3vzxsB1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHreEBifCCVZYK0O|PDqA>? MkWzNlAxPTN5OEG=
MDA-MB-453  NUT0foFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWO3T3ZEPS12MDFOwG0> MXG3NkBp M2LqeGlEPTBib3[gNVAh|ryP M1XS[FIxODV|N{ix
PC-3 NUjXeXhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfKOU01OCEQvF2= MX:3NkBp NVH1XFFyUUN3MDDv[kAyOCEQvF2= M3H5b|IxODV|N{ix

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
p-AKT(Ser473) / p-AKT(Thr308); 

PubMed: 22739265     


Cells were serum-starved for 6 h and treated with KU-55933 (10 µmol/L) for 1 h before treatment with insulin (100 nmol/L) for 45 min. Cells were lysed, and cell lysates were subjected to SDS-PAGE and Western blotting for the detection of phospho-Akt at Se䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖

PARP / Cleaved PARP / Caspase-3 / Cleaved caspase-3 ; 

PubMed: 22739265     


ATM inhibition by KU-55933 induces apoptosis in differentiated but not undifferentiated SH-SY5Y cells. Cells were starved for 6 h in serum-free medium. KU-55933 (10 µmol/L) was added 1 h before insulin (100 nmol/L) treatment. After 3 h of insulin stimulat䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤

ATM-S1981 / ATM / p-p53(S15) / p53 ; 

PubMed: 20639198     


Antioxidant and ATM inhibitors blocked phosphorylation of ATM-S1981, Akt-S473, and p53-S15 as stimulated by H2O2 exposure. Cells were treated with 100 μm H2O2 for 30 min in the absence or presence of KU-55933. Whole cell lysates were subjected to Western 䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖

p21 / p27 / p53 ; 

PubMed: 20177072     


HMGE cells were incubated for the indicated times with 1 μm KU-55933 or DMSO. Total protein extracts were analyzed by Western blotting for p21WAF1/CIP1, p27KIP1, p53, or β-actin.

22739265 20639198 20177072
Immunofluorescence
p-S824 KAP1 / ZEBRA ; 

PubMed: 28249048     


HH514-16 cells were treated with NaB (upper panel) or NaB plus KU-55933 (1μM; middle panel) or NaB plus Torin1 (0.5μM; lower panel) for 24 hours and stained with anti-phospho KAP1 (S824) plus anti-ZEBRA antibodies and visualized at 1000X magnification.

28249048
In vivo Suppression of ATM-dependent STAT3 activation by KU-55933 enhances TRAIL-mediated apoptosis through up-regulation of surface DR5 expression, whereas suppression of both STAT3 and NF-κB appeares to be involved in down-regulation of cFLIP accompanied by an additional increase in apoptotic levels. The ATM inhibitor KU-55933 affectes TRAIL-mediated apoptosis more strongly than the JAK2 inhibitor, AG490, or overexpression of STAT3β. [3]

Protocol

Kinase Assay:

[1]
+ Expand

Purified enzyme assays:

ATM for use in the in vitro assay is obtained from HeLa nuclear extract by immunoprecipitation with rabbit polyclonal antiserum raised to the COOH-terminal 400 amino acids of ATM in buffer containing 25 mM HEPES (pH 7.4), 2 mM MgCl2, 250 mM KCl, 500 μM EDTA, 100 μM Na3VO4, 10% v/v glycerol, and 0.1% v/v Igepal. ATM-antibody complexes are isolated from nuclear extract by incubating with protein A-Sepharose beads for 1 hour and then through centrifugation to recover the beads. In the well of a 96-well plate, ATM-containing Sepharose beads are incubated with 1 μg of substrate glutathione S-transferase–p53N66 (NH2-terminal 66 amino acids of p53 fused to glutathione S-transferase) in ATM assay buffer [25 mM HEPES (pH 7.4), 75 mM NaCl, 3 mM MgCl2, 2 mM MnCl2, 50 μM Na3VO4, 500 μM DTT, and 5% v/v glycerol] at 37 °C in the presence or absence of inhibitor. After 10 minutes with gentle shaking, ATP is added to a final concentration of 50 μM and the reaction continued at 37 °C for an additional 1 hour. The plate is centrifuged at 250 × g for 10 minutes (4 °C) to remove the ATM-containing beads, and the supernatant is removed and transferred to a white opaque 96-well plate and incubated at room temperature for 1.5 hours to allow glutathione S-transferase-p53N66 binding. This plate is then washed with PBS, blotted dry, and analyzed by a standard ELISA technique with a phospho-serine 15 p53 antibody. The detection of phosphorylated glutathione S-transferase-p53N66 substrate is performed in combination with a goat antimouse horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence solution is used to produce a signal and chemiluminescent detection is carried out.
Cell Research:

[1]
+ Expand
  • Cell lines: U2OS cells
  • Concentrations: 10 μM
  • Incubation Time: 2 hours
  • Method:

    U2OS cells are exposed to ionizing radiation (3, 5, or 15 Gy) or UV (5 or 50 J/m2) and the ATM response determined by Western blot analysis of p53 serine 15 phosphorylation and stabilization of wild-type p53. Whole cell extracts are obtained from each time point, proteins separated by SDS-PAGE, and the ATM-specific increase in phosphorylated serine 15 measured with a p53 phospho-serine 15 specific antibody. Overall p53 stabilization with time is also observed with a p53-specific antibody (DO-1). Similarly, for studying ATM-dependent phosphorylations on H2AX, CHK1, NBS1, and SMC1, the following antibodies are used: CHK1 phospho-serine 345 and NBS1 phospho-serine 343 antibodies. Histone H2A (H-124) and CHK1 antibodies are also used, as well as SMC1 and SMC1 phospho-serine 966 antibodies. For determination of a cellular IC50 for KU-55933, the peak response time for p53 serine 15 phosphorylation of 2 hours is used to monitor inhibition of ATM. KU-55933 is titrated onto cells and preincubated for 1 hour before ionizing radiation. Using scanning densitometry, the percentage inhibition relative to vehicle control is calculated, and the IC50 value is calculated as for the in vitro determinations.


    (Only for Reference)
Animal Research:

[3]
+ Expand
  • Animal Models: BALB/c nu/nu nude mice bearing LU1205 cells
  • Formulation: --
  • Dosages: 10 μM
  • Administration: --
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 33 mg/mL (83.44 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO and 47.5% PEG300
For best results, use promptly after mixing. 		10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 395.49
Formula

C21H17NO3S2
CAS No. 587871-26-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
selleck catalog

ATM/ATR Signaling Pathway Map

ATM/ATR Inhibitors with Unique Features

Related ATM/ATR Products4

  • AZD6738 New

    AZD6738 is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2.

  • CHIR-99021 (CT99021) New

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.

  • Dorsomorphin (Compound C) New

    Dorsomorphin is a potent, reversible, selective AMPK inhibitor with Ki of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.

  • VE-821

    VE-821 is a potent and selective ATP competitive inhibitor of ATR with Ki/IC50 of 13 nM/26 nM in cell-free assays, shows inhibition of H2AX phosphorylation, minimal activity against PIKKs ATM, DNA-PK, mTOR and PI3Kγ.

  • KU-60019

    KU-60019 is an improved analogue of KU-55933, with IC50 of 6.3 nM for ATM in cell-free assays, 270- and 1600-fold more selective for ATM than DNA-PK and ATR,and is a highly effective radiosensitizer.

    Features:Improved analog of KU-55933, and is more effective at blocking ATM-mediated DDR events.

  • Berzosertib (VE-822|VX970|M6620)

    VE-822 is an ATR inhibitor with IC50 of 19 nM in HT29 cells.

    Features:VE-822 is a highly selective and potent derivative of the ATR inhibitor VE-821.

  • Chloroquine diphosphate

    Chloroquine diphosphate is a 4-aminoquinoline anti-malarial and anti-rheumatoid agent, also acting as an ATM activator.

  • AZ20

    AZ20 is a novel potent and selective inhibitor of ATR kinase with IC50 of 5 nM in a cell-free assay, 8-fold selectivity over mTOR.

    Features:AZ20 is the first reported inhibitor of ATR protein kinase demonstrating tumor growth inhibition in vivo.

  • CP-466722

    CP-466722 is a potent and reversible ATM inhibitor, does not affect ATR and inhibits PI3K or PIKK family members in cells.

  • ETP-46464

    ETP-46464 is a potent and selective inhibitor of ATR with IC50 of 25 nM.

    Features:Selective ATR inhibitor and particularly toxic to p53-deficient cancer cells. Often used as a pharmacologic probe due to its ideal pharmacological properties.

Tags: buy KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) supplier | purchase KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) cost | KU-55933 (ATM Kinase Inhibitor) manufacturer | order KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID